ArticlePloS one2025
Regulatory influence of α-Pinene on MATN3 expression in hepatocellular carcinoma: Extending to pan-cancer analysis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the search for novel therapeutic strategies against cancer, natural compounds such as α-Pinene, a bioactive monoterpene predominantly found in coniferous trees, have emerged as potential modulators of oncogenic processes. The primary objective of this study was to investigate whether α-Pinene can regulate the expression of MATN3 (Matrilin-3), a gene previously associated with poor prognosis in various cancers. Our central hypothesis is that α-Pinene exerts its anticancer effects, at least in part, by downregulating MATN3, thereby impacting oncogenic signaling. The rationale for selecting MATN3 as a target lies in its demonstrated overexpression in multiple cancer types and its established role as both a prognostic marker and a contributor to tumor progression. Extending our research through a comprehensive pan-cancer analysis, we confirmed the association between high MATN3 expression and poor prognosis across multiple cancer types. Further exploration revealed a strong correlation between MATN3 expression and immune infiltration, as well as significant associations with key immunomodulatory genes, suggesting an intricate role of MATN3 in the tumor immune environment. Enrichment analysis pointed to the involvement of MATN3 in the PI3K-AKT signaling pathway. Additionally, we identified connections between MATN3 and extracellular matrix (ECM)-related mechanisms.The downregulation of MATN3 by α-Pinene in HepG2 cells suggests a novel mechanism by which α-Pinene may exert anticancer effects, potentially through the disruption of key oncogenic and immune-related pathways. This study not only underscores the anticancer potential of α-Pinene but also establishes MATN3 as a critical target and biomarker across a spectrum of cancers. Our findings advocate for further clinical investigations into α-Pinene's therapeutic potential, particularly focusing on its impact on MATN3 and related pathways in diverse cancer contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.